CareLit · DOI-Nachweis · Pneumologie
Exacerbator subtypes in the TIOtropium Safety and Performance In Respimat (TIOSPIR™) trial
DOI 10.1055/s-0035-1544714
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Geßner, P Calverley, D Dusser, R Wise, G Pledger, R Dahl, A Mueller, J Montero Caballero, A Anzueto
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Cardiovascular (CV) comorbidities in chronic obstructive pulmonary disease (COPD) patients are frequent. We evaluated whether baseline variables can predict mortality and CV events in the TIOSPIR trial (17,116 COPD patients receiving tiotropium Respimat 5 or 2.5µg or HandiHaler 18µg for a mean of 2.3 yrs). Methods: Exploratory pooled analysis from TIOSPIR to determine prognostic factors for mortality, ma…
Zitieren
Zitierempfehlung
C Geßner, P Calverley, D Dusser, R Wise, G Pledger, R Dahl, A Mueller, J Montero Caballero, A Anzueto (2015) Exacerbator subtypes in the TIOtropium Safety and Performance In Respimat (TIOSPIR™) trial. Pneumologie (02). https://doi.org/10.1055/s-0035-1544714
Mit CareLit weiterarbeiten